Product Description: Erzotabart is an IgG1-kappa, anti-CD38 (ADP-ribosyl cyclase 1, cyclic ADP-ribose hydrolase 1, cADPr hydrolase 1, cADPR1) Homo sapiens monoclonal antibody. Erzotabart shows antineoplastic activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 4, 2022.
CAS Number: 2430792-01-9
Molecular Weight: N/A
Research Area: Cancer
Solubility: H2O
Target: CD38